Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041477 | 1.00 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL22197915 | 1.00 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL27041463 | 1.00 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29634835 | 0.90 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL22636086 | 0.90 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31369861 | 0.90 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31370166 | 0.90 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL118105 | 0.90 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31693430 | 0.89 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL119618 | 0.89 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | KMT2A 2905/4885EPHX2 2688/4885FABP5 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.